Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Early Vascular Ageing and Cellular Senescence in Chronic Kidney Disease.

Dai L, Qureshi AR, Witasp A, Lindholm B, Stenvinkel P.

Comput Struct Biotechnol J. 2019 Jun 18;17:721-729. doi: 10.1016/j.csbj.2019.06.015. eCollection 2019. Review.

2.

Chemerin inhibits vascular calcification through ChemR23 and is associated with lower coronary calcium in chronic kidney disease.

Carracedo M, Witasp A, Qureshi AR, Laguna-Fernandez A, Brismar T, Stenvinkel P, Bäck M.

J Intern Med. 2019 Jun 13. doi: 10.1111/joim.12940. [Epub ahead of print]

PMID:
31197872
3.

Serum concentration and vascular expression of adiponectin are differentially associated with the diabetic calcifying peripheral arteriopathy.

Aubert CE, Liabeuf S, Amouyal C, Kemel S, Lajat-Kiss F, Lacorte JM, Halbron M, Carlier A, Salem JE, Funck-Brentano C, Perisic Matic L, Witasp A, Stenvinkel P, Phan F, Massy ZA, Hartemann A, Bourron O.

Diabetol Metab Syndr. 2019 Apr 29;11:32. doi: 10.1186/s13098-019-0429-7. eCollection 2019.

4.

Correlation of computed tomography with carotid plaque transcriptomes associates calcification with lesion-stabilization.

Karlöf E, Seime T, Dias N, Lengquist M, Witasp A, Almqvist H, Kronqvist M, Gådin JR, Odeberg J, Maegdefessel L, Stenvinkel P, Matic LP, Hedin U.

Atherosclerosis. 2019 May 11. pii: S0021-9150(19)30410-1. doi: 10.1016/j.atherosclerosis.2019.05.005. [Epub ahead of print]

5.

The G-protein coupled receptor ChemR23 determines smooth muscle cell phenotypic switching to enhance high phosphate-induced vascular calcification.

Carracedo M, Artiach G, Witasp A, Clària J, Carlström M, Laguna-Fernandez A, Stenvinkel P, Bäck M.

Cardiovasc Res. 2019 Aug 1;115(10):1557-1566. doi: 10.1093/cvr/cvy316.

PMID:
30597013
6.

Fibroblast growth factor 23 is associated with fractional excretion of sodium in patients with chronic kidney disease.

Xu H, Hashem A, Witasp A, Mencke R, Goldsmith D, Barany P, Bruchfeld A, Wernerson A, Carrero JJ, Olauson H.

Nephrol Dial Transplant. 2018 Oct 11. doi: 10.1093/ndt/gfy315. [Epub ahead of print]

PMID:
30312430
7.

Current epigenetic aspects the clinical kidney researcher should embrace.

Witasp A, Van Craenenbroeck AH, Shiels PG, Ekström TJ, Stenvinkel P, Nordfors L.

Clin Sci (Lond). 2017 Jun 30;131(14):1649-1667. doi: 10.1042/CS20160596. Print 2017 Jul 15. Review.

PMID:
28667065
8.

CDKN2A/p16INK4a expression is associated with vascular progeria in chronic kidney disease.

Stenvinkel P, Luttropp K, McGuinness D, Witasp A, Qureshi AR, Wernerson A, Nordfors L, Schalling M, Ripsweden J, Wennberg L, Söderberg M, Bárány P, Olauson H, Shiels PG.

Aging (Albany NY). 2017 Feb 9;9(2):494-507. doi: 10.18632/aging.101173.

9.

Increased circulating sclerostin levels in end-stage renal disease predict biopsy-verified vascular medial calcification and coronary artery calcification.

Qureshi AR, Olauson H, Witasp A, Haarhaus M, Brandenburg V, Wernerson A, Lindholm B, Söderberg M, Wennberg L, Nordfors L, Ripsweden J, Barany P, Stenvinkel P.

Kidney Int. 2015 Dec;88(6):1356-1364. doi: 10.1038/ki.2015.194. Epub 2015 Sep 2.

PMID:
26331407
10.

How can genetics and epigenetics help the nephrologist improve the diagnosis and treatment of chronic kidney disease patients?

Witasp A, Ekström TJ, Schalling M, Lindholm B, Stenvinkel P, Nordfors L.

Nephrol Dial Transplant. 2014 May;29(5):972-80. doi: 10.1093/ndt/gfu021. Epub 2014 Feb 24. Review.

PMID:
24569498
11.

Inflammatory biomarker pentraxin 3 (PTX3) in relation to obesity, body fat depots and weight loss.

Witasp A, Carrero JJ, Michaëlsson K, Ahlström H, Kullberg J, Adamsson V, Risérus U, Larsson A, Helmersson-Karlqvist J, Lind L, Stenvinkel P, Arnlöv J.

Obesity (Silver Spring). 2014 May;22(5):1373-9. doi: 10.1002/oby.20695. Epub 2014 Jan 25.

12.

Evaluation of the association of plasma pentraxin 3 levels with type 2 diabetes and diabetic nephropathy in a Malay population.

Abu Seman N, Witasp A, Wan Mohamud WN, Anderstam B, Brismar K, Stenvinkel P, Gu HF.

J Diabetes Res. 2013;2013:298019. doi: 10.1155/2013/298019. Epub 2013 Nov 20.

13.

Novel insights from genetic and epigenetic studies in understanding the complex uraemic phenotype.

Witasp A, Ekström TJ, Lindholm B, Stenvinkel P, Schalling M, Nordfors L.

Nephrol Dial Transplant. 2014 May;29(5):964-71. doi: 10.1093/ndt/gft428. Epub 2013 Nov 13. Review.

PMID:
24235077
14.

Elevated circulating levels and tissue expression of pentraxin 3 in uremia: a reflection of endothelial dysfunction.

Witasp A, Rydén M, Carrero JJ, Qureshi AR, Nordfors L, Näslund E, Hammarqvist F, Arefin S, Kublickiene K, Stenvinkel P.

PLoS One. 2013 May 3;8(5):e63493. doi: 10.1371/journal.pone.0063493. Print 2013.

15.

Genetic studies in chronic kidney disease: interpretation and clinical applicability.

Witasp A, Nordfors L, Carrero JJ, Luttropp K, Lindholm B, Schalling M, Stenvinkel P.

J Nephrol. 2012 Nov-Dec;25(6):851-64. doi: 10.5301/jn.5000216. Review.

PMID:
23042432
16.

Genetic studies in chronic kidney disease: basic concepts.

Nordfors L, Luttropp K, Carrero JJ, Witasp A, Stenvinkel P, Lindholm B, Schalling M.

J Nephrol. 2012 Mar-Apr;25(2):141-9. doi: 10.5301/jn.5000145. Review.

PMID:
22437428
17.

Antidepressant treatment is associated with epigenetic alterations in the promoter of P11 in a genetic model of depression.

Melas PA, Rogdaki M, Lennartsson A, Björk K, Qi H, Witasp A, Werme M, Wegener G, Mathé AA, Svenningsson P, Lavebratt C.

Int J Neuropsychopharmacol. 2012 Jun;15(5):669-79. doi: 10.1017/S1461145711000940. Epub 2011 Jun 20.

PMID:
21682946
18.

Expression of osteoprotegerin in human fat tissue; implications for chronic kidney disease.

Witasp A, Carrero JJ, Hammarqvist F, Qureshi AR, Heimbürger O, Schalling M, Lindholm B, Nordfors L, Stenvinkel P.

Eur J Clin Invest. 2011 May;41(5):498-506. doi: 10.1111/j.1365-2362.2010.02432.x. Epub 2010 Dec 3.

PMID:
21128937
19.

Increased expression of pro-inflammatory genes in abdominal subcutaneous fat in advanced chronic kidney disease patients.

Witasp A, Carrero JJ, Heimbürger O, Lindholm B, Hammarqvist F, Stenvinkel P, Nordfors L.

J Intern Med. 2011 Apr;269(4):410-9. doi: 10.1111/j.1365-2796.2010.02293.x. Epub 2010 Nov 5.

20.

Is fetuin-A a mortality risk factor in dialysis patients or a mere risk marker? A Mendelian randomization approach.

Verduijn M, Prein RA, Stenvinkel P, Carrero JJ, le Cessie S, Witasp A, Nordfors L, Krediet RT, Boeschoten EW, Dekker FW.

Nephrol Dial Transplant. 2011 Jan;26(1):239-45. doi: 10.1093/ndt/gfq402. Epub 2010 Jul 5.

PMID:
20605840
21.

Expression of inflammatory and insulin signaling genes in adipose tissue in response to elective surgery.

Witasp A, Nordfors L, Schalling M, Nygren J, Ljungqvist O, Thorell A.

J Clin Endocrinol Metab. 2010 Jul;95(7):3460-9. doi: 10.1210/jc.2009-2588. Epub 2010 May 5.

PMID:
20444921
22.

Visfatin is increased in chronic kidney disease patients with poor appetite and correlates negatively with fasting serum amino acids and triglyceride levels.

Carrero JJ, Witasp A, Stenvinkel P, Qureshi AR, Heimbürger O, Bárány P, Suliman ME, Anderstam B, Lindholm B, Nordfors L, Schalling M, Axelsson J.

Nephrol Dial Transplant. 2010 Mar;25(3):901-6. doi: 10.1093/ndt/gfp587. Epub 2009 Nov 30.

PMID:
19948877
23.

Increased expression of inflammatory pathway genes in skeletal muscle during surgery.

Witasp A, Nordfors L, Schalling M, Nygren J, Ljungqvist O, Thorell A.

Clin Nutr. 2009 Jun;28(3):291-8. doi: 10.1016/j.clnu.2009.03.003. Epub 2009 Apr 5.

PMID:
19346035
24.

Circulating levels of visfatin/pre-B-cell colony-enhancing factor 1 in relation to genotype, GFR, body composition, and survival in patients with CKD.

Axelsson J, Witasp A, Carrero JJ, Qureshi AR, Suliman ME, Heimbürger O, Bárány P, Lindholm B, Alvestrand A, Schalling M, Nordfors L, Stenvinkel P.

Am J Kidney Dis. 2007 Feb;49(2):237-44.

PMID:
17261426
25.

Use of single-nucleotide polymorphisms in the search for genetic modifiers of the uremic phenotype.

Witasp A, Nordfors L, Lindholm B, Stenvinkel P.

J Ren Nutr. 2007 Jan;17(1):17-22. Review.

PMID:
17198927
26.

Changes in fat mass correlate with changes in soluble sCD163, a marker of mature macrophages, in patients with CKD.

Axelsson J, Møller HJ, Witasp A, Qureshi AR, Carrero JJ, Heimbürger O, Bárány P, Alvestrand A, Lindholm B, Moestrup SK, Stenvinkel P.

Am J Kidney Dis. 2006 Dec;48(6):916-25.

PMID:
17162146

Supplemental Content

Loading ...
Support Center